Revolution Medicines Inc
Change company Symbol lookup
Select an option...
RVMD Revolution Medicines Inc
BAC Bank of America Corp
KVHI KVH Industries Inc
SUP Superior Industries International Inc
FB Facebook Inc
V Visa Inc
FL Foot Locker Inc
DPZ Domino's Pizza Inc
CTMX CytomX Therapeutics Inc
AVIVF Advanced Info Service PCL
Go

Company profile

Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.

Closing Price
$32.16
Day's Change
-1.01 (-3.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.76
Day's Low
31.10
Volume
341,762
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Social data discovery, filtering, and analysis provided by LikeFolio: © SwanPowers, LLC

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

TD Ameritrade provides access to social media platforms on an "as is" basis, and cannot guarantee that content from social media is always available, that it contains all content from the social media source, or that it contains the most recent or most relevant information from the source.